Product Details
| Product Name:
Torbafylline |
CAS No.:
105102-21-4 |
| Purity:
99.96% |
Supply Ability:
10g |
| Release date:
2026/05/23 |
Product Introduction
Bioactivity
| Name | Torbafylline |
| Description | Torbafylline, a xanthine derivative, is a phosphodiesterase (PDE) inhibitor that attenuates burn-induced protein hydrolysis in rat skeletal muscle through activation of the PDE4/cAMP/EPAC/PI3K/Akt pathway, and inhibits the enhanced ubiquitin-proteasome-dependent protein hydrolysis in skeletal muscle of cancer- and sepsis-prone rats. |
| In vivo | Torbafylline (25 mg/kg per day; oral; three weeks) decreased fatigue to 68%. The blood flow in ligated muscles increased to a much smaller extent than in control muscles, and this smaller increase was attenuated by Torbafylline. A chronic decrease in the blood supply resulted in a significant shortening of the running time.[1]
Torbafylline (25 mg/kg p.o.; 2 times a day; 2 weeks) decrease in running time was reversed by chronic treatment of Torbafylline. This improved performance may be explained by a decreased accumulation of lactate in muscles with a limited blood supply due to the effect of Torbafylline to increase the release of lactate from ischaemic muscles.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 25 mg/mL (73.88 mM), Sonication is recommended.
|
| Keywords | PI3K | EPAC | CAMP PDE |
| Inhibitors Related | Musk ketone | Balipodect | Myricetin | Creatine monohydrate | Hyaluronic acid | D(+)-Raffinose pentahydrate | Theobromine | Apremilast | Indomethacin | Methyl eugenol | Sildenafil citrate | Doxofylline |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Hematonosis Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States